登录 | 注册    关注公众号  
微信公众号
搜索
 > 【VEGF165】

VEGF165信息

英文名称:Vascular endothelial growth factor A
中文名称:血管内皮生长因子A
靶点别称:Vascular Endothelial Growth Factor,VEGF-A,MVCD1,Vascular endothelial growth factor A,VEGF,VEGFA,VPF,Vascular Endothelial Growth Factor A165,Vascular permeability factor,Vascular Endothelial Growth Factor A121
上市药物数量:40
临床药物数量:63
最高研发阶段:批准上市

VEGF165分子别名

RP1-261G23.1,MGC70609,MVCD1,VEGFA,VPF

VEGF165分子背景

VEGF165 is the most abundant splice variant of VEGF-A. VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability. VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes. VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix. VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2. VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 that function to enhance VEGFR2 signaling. Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin. VEGF plays a key role in tumor angiogenesis in many cancers.

VEGF165上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验

VEGF165临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验

消息提示

请输入您的联系方式,再点击提交!

确定